Duality Biotherapeutics, Inc. (DUALITYBIO) has released its Monthly Return for the period ended 31 May 2026, detailing modest changes to its share capital structure and confirming adherence to Hong Kong Stock Exchange (HKEX) public float requirements.\n\nKey Share Capital Metrics\n• Authorised share capital remained unchanged at 200 million ordinary shares with a par value of USD 0.0001 each, representing total authorised capital of USD 20,000.\n\nMovements in Issued and Treasury Shares\n• Issued shares (excluding treasury shares) increased by 47.80 thousand month-on-month to 90.48 million.\n• Treasury shares rose to 119.80 thousand after the company repurchased 119.80 thousand shares on 26–29 May 2026 at prices ranging from HKD 212.88 to HKD 223.19 per share.\n• Total shares in issue (including treasury stock) reached 90.60 million at month-end.\n\nEquity Incentive Activity\n• Under the Pre-IPO Equity Incentive Plan, 167.60 thousand options were exercised, resulting in the same number of new shares being issued.\n• Option exercises generated HKD 1.30 million in proceeds.\n• 12.50 thousand options were cancelled during the month, leaving 18.45 million options outstanding and 13.89 million options still available for future issuance.\n\nPublic Float and Compliance\n• DualityBio confirmed that it met the HKEX Main Board minimum public float threshold of 25% as of 31 May 2026.\n\nOverall Share Count Dynamics\nCombining option exercises and share repurchases, the company recorded a net issuance of 47.80 thousand ordinary shares during May 2026, reflecting disciplined capital management while preserving compliance with listing requirements.